m6A modification: recent advances, anticancer targeted drug discovery and beyond

• Published in: Molecular cancer Vol. 21; no. 1; pp. 52 - 21
• Main Authors: Deng, Li-Juan, Deng, Wei-Qing, Fan, Shu-Ran, Chen, Min-Feng, Qi, Ming, Lyu, Wen-Yu, Qi, Qi, Tiwari, Amit K., Chen, Jia-Xu, Zhang, Dong-Mei, Chen, Zhe-Sheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 14.02.2022; BioMed Central; BMC
• Subjects: Adenosine - chemistry; Antineoplastic drugs; Antitumor agents; Apoptosis; Artificial Intelligence; Binding sites; Cancer; Chemosynthesis; Drug delivery; Drug Discovery; Drug resistance; Gene expression; Humans; Intellectual disabilities; m6A; Medical prognosis; Metastasis; Methyltransferases; Modulators; N6-methyladenosine; Natural product; Natural products; Neoplasms - drug therapy; Neoplasms - genetics; Prognosis; Proteins; Review; Therapeutic targets; Traditional medicine; Tumors; Natural product; m6A; Chemosynthesis; Drug discovery; Modulators; Cancer

Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platfo...